**S8 Table: Assessments of instrument exogeneity and relevance**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Dabigatran** | **Sitagliptin** | **Aliskiren** |
| *Panel A. Partial assessment of instrument exogeneity*(overidentification test) |
| Test statistic[p-value] | 47.3[0.031] | 37.0[0.213] | 30.3[0.500] |
| *Panel B. Individual assessments of instrument relevance for each network*(first-stage *F*-statistic)Network: |
| Patient-sharing | 25.3 | 30.4 | 12.8 |
| Medical group | 5.2 | 6.3 | 3.8 |
| Hospital | 17.5 | 28.4 | 22.4 |
| Training | 2.6 | 2.7 | 1.6 |
| *Panel C. Joint assessment of instrument relevance, with medical group and training networks*(minimum eigenvalue statistic) |
| Test statistic | 5.3 | 3.4 | 2.1 |
| *Panel D. Joint assessment of instrument relevance, without medical group and training networks*(minimum eigenvalue statistic) |
| Test statistic | 51.4 | 44.3 | 17.4 |